Abstract:Background: Hemodialysis patients, who are often excluded from cardiovascular (CV) clinical trials, are associated with higher CV morbidity and mortality. The risk stratification scheme for these patients is lacking. Therefore, this investigation examined the independent CV prognostic value of high-sensitive cardiac troponin T (hs-cTnT) and added prognostic value over echocardiographic parameters and other clinical risk predictors in asymptomatic stable maintenance hemodialysis (MHD) patients. Methods: 181 patients with end-stage renal disease undergoing MHD were eligible from the dialysis center of Tongren Hospital, Shanghai Jiao Tong University School of Medicine between October 2017 and September 2018. These patients were followed until September 2020 or until death. The median follow-up was 31 (IQR: 21-33) months. Outcome measures were all-cause mortality, first fatal or nonfatal CV events (CVEs), and 4-point composite major adverse CVEs (MACE). We performed multivariable Cox regression analysis using demographic, clinical, laboratory, and echocardiographic data to identify predictors of CV outcomes. We also evaluated the increased discriminative value associated with the addition of echocardiographic parameters and hs-cTnT using net reclassification improvement (NRI) and integrated discrimination improvement (IDI). Results: During follow-up, 37 patients died, 84 patients suffered one or more CVEs, and 78 patients developed 4-point MACE. In univariable analyses, age, dialysis vintage, diastolic blood pressure, parathyroid hormone concentrations, hs-cTnT, B-type natriuretic peptide, left ventricular mass index (LVMI), and E/E ' predicted all end points. hs-cTnT remained a strong predictor for each end point in multivariate analysis, whereas LVMI and E/E ' did not. The addition of hs-cTnT on top of clinical and echocardiographic variables was associated with improvements in reclassification for CVEs (NRI = 44.6% [15.9-74.3%], IDI = 15.9% [5.7-31.0%], all p < 0.001), all-cause mortality (NRI = 35.5% [10.1-50.2%], p < 0.001, IDI = 4.4% [1.3-8.5%], p = 0.005), and 4-point MACE (NRI = 47.2% [16.1-64.9%], p < 0.001, IDI = 16.9% [5.5-37.3%], p = 0.005). Adding echocardiographic variables on top of clinical variables and hs-cTnT was not associated with significant improvements in NRI and IDI (all p > 0.05). Conclusions: Our data suggest that hs-cTnT is a powerful independent predictor of CV outcome and all-cause mortality in stable MHD patients. The additional use of echocardiography for improvement of risk stratification is not supported by our results.

Serum Pentraxin3: Its Relationship with left Ventricular Mass Index and its role as a Predictor for Cardiovascular Mortality in Hemodialysis Patients

Correlation of plasma pentraxin 3 with cardiovascular disease in hemodialysis patients

Plasma Pentraxin 3 is Associated with Cardiovascular Disease in Hemodialysis Patients.

Plasma Pentraxin 3 Is Closely Associated with Peripheral Arterial Disease in Hemodialysis Patients and Predicts Clinical Outcome: A 6-Year Follow-Up.

Inverse relationship between the inflammatory marker pentraxin-3, fat body mass, and abdominal obesity in end-stage renal disease

Relationships between Plasma Pentraxin 3 Levels and Inflammation Markers Patients with Tunneled Permanent Catheter in Hemodialysis

Pentraxin-3 Predicts Long-Term Cardiac Events in Patients with Chronic Heart Failure.

Plasma Pentraxin 3 May Be A Better Marker Of Peripheral Artery Disease In Hemodialysis Patients Than C-Reactive Protein

Implication of plasma pentraxin 3 in peripheral arterial disease of hemodialysis patients

Associations between pentraxin 3 and severity of coronary artery disease.

Study on the relationship between serum level of Pentraxin 3 and short-term prognosis in patients with acute coronary syndrome

Assessment of serum cardiac troponin T and C-reactive protein in predicting hemodialysis outcome

Role of serum pentraxin-3 levels in patients with and without diabetic nephropathy

Serum pentraxin 3 levels in term neonates with persistent pulmonary hypertension

Prognostic value of serum pentraxin 3 for intracerebral hemorrhage mortality

High Alkaline Phosphatase and Low Intact Parathyroid Hormone Associate with Worse Clinical Outcome in Peritoneal Dialysis Patients

Plasma Netrin-1 & cardiovascular risk in children with end stage renal disease

Prognostic Efficacy of Combined Index of Cardiac Biomarkers for Cardiovascular and All-Cause Mortality on Hemodialysis Patients

The assessment of pentraxin 3: a diagnostic and prognostic biomarker in lower respiratory tract infections in children

Serum pentraxin 3 as a biomarker for prognosis of acute minor stroke due to large artery atherosclerosis

High-Sensitive Cardiac Troponin T for Prediction of Cardiovascular Outcomes in Stable Maintenance Hemodialysis Patients: A 3-Year Prospective Study